Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The CooperMEX:COO 88 EV-to-EBITDA is 17.28 as of Jul. 23, 2026, which is 22% below its 10-year median of 22.15. GuruFocus rates MEX:COO with a GF Score™ of 88/100 and a GF Value™ of MXN1,788.74 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 510 Medical Devices & Instruments companies, The Cooper ranks worse than 62.16% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, The Cooper's enterprise value is MXN278,841 Mil.
The Cooper's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 was MXN16,139 Mil. Therefore, The Cooper's EV-to-EBITDA for today is 17.28.
The historical rank and industry rank for The Cooper's EV-to-EBITDA or its related term are showing as below:
MEX:COO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 13.88 Med: 22.15 Max: 35.46
Current: 17.99
During the past 13 years, the highest EV-to-EBITDA of The Cooper was 35.46. The lowest was 13.88. And the median was 22.15.
MEX:COO's EV-to-EBITDA is ranked worse than 62.16% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.08
vs MEX:COO: 17.99
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
The Cooper (MEX:COO) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The Cooper's share price for today is MXN1244.30.
The Cooper's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN21.743.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for The Cooper's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:COO vs SOLV, ALGN, BAX: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, The Cooper's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cooper EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, The Cooper's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where The Cooper's EV-to-EBITDA falls into.
The Cooper's current Enterprise Value is MXN278,841 Mil.
The Cooper's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN16,139 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Cooper (MEX:COO) has a EV-to-EBITDA of 17.28 as of Jul. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on The Cooper. This is 22% below median its historical median of 22.15. Over the past decade, The Cooper's EV-to-EBITDA has ranged from 13.88 to 35.46. According to the industry distribution chart, The Cooper ranks #317 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 62.2%.
Is The Cooper's EV-to-EBITDA too high?
The Cooper's current EV-to-EBITDA of 17.28 is 22% below median its 10-year median of 22.15. Over the past 10 years, this metric has ranged from a low of 13.88 to a high of 35.46. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.08. The Cooper's value of 17.28 is 22.7% above this industry median. Based on the distribution chart, The Cooper ranks #317 out of 510 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, The Cooper has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cooper's EV-to-EBITDA compare to SOLV and ALGN?
According to the Medical Devices & Instruments industry distribution chart, The Cooper ranks #317 out of 510 companies for EV-to-EBITDA. This places The Cooper in the lower half of its industry. The industry median EV-to-EBITDA is 14.08. The Cooper's value of 17.28 is 22.7% above this benchmark. Historically, The Cooper's own EV-to-EBITDA has ranged from 13.88 to 35.46 over the past decade. While the company's 10-year median is 22.15 vs. the industry median of 14.08, The Cooper has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.08, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Cooper's current EV-to-EBITDA of 17.28 is 22.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on The Cooper. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cooper's current EV-to-EBITDA is 17.28, which is 22% below median its own 10-year median of 22.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cooper stock overvalued right now?
Based on GuruFocus' analysis, The Cooper (MEX:COO) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,788.74, compared to a current price of MXN1,244.30 — trading 30.4% below its estimated fair value. The current EV-to-EBITDA is 17.28, which is 22% below median its 10-year median of 22.15 and 22.7% above the Medical Devices & Instruments industry median of 14.08. The Cooper's overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For The Cooper (MEX:COO), the current EV-to-EBITDA is 17.28 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cooper (MEX:COO) Overvalued in 2026?
Based on GuruFocus' analysis, The Cooper stock appears to be undervalued.
The current stock price of MXN1,244.30 is trading 30.4% below its estimated GF Value™ of MXN1,788.74.
GuruFocus considers The Cooper to be Significantly Undervalued.
Key valuation signals for MEX:COO:
EV-to-EBITDA: 17.28 (22% below median its 10-year median of 22.15)
GF Value™: MXN1,788.74 vs. price of MXN1,244.30 (30.4% below fair value)
Industry Position: 22.7% above the Medical Devices & Instruments median (#317 of 510)
No single metric tells the full story. See the MEX:COO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
88GF Score
Get the complete analysis for MEX:COO
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:COO has been successfully added to your 
